263 related articles for article (PubMed ID: 30445633)
1. Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.
Fan H; Yu X; Zou Z; Zheng W; Deng X; Guo L; Jiang W; Zhan Q; Lu SH
Carcinogenesis; 2019 Jul; 40(5):669-679. PubMed ID: 30445633
[TBL] [Abstract][Full Text] [Related]
2. Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo.
Cai X; Hu X; Tan X; Cheng W; Wang Q; Chen X; Guan Y; Chen C; Jing X
PLoS One; 2015; 10(7):e0133349. PubMed ID: 26196392
[TBL] [Abstract][Full Text] [Related]
3. Ornithine decarboxylase inhibition downregulates multiple pathways involved in the formation of precancerous lesions of esophageal squamous cell cancer.
Xie Y; Dong CD; Wu Q; Jiang Y; Yao K; Zhang J; Zhao S; Ren Y; Yuan Q; Chen X; Liu Z; Zhao J; Liu K
Mol Carcinog; 2020 Feb; 59(2):215-226. PubMed ID: 31793679
[TBL] [Abstract][Full Text] [Related]
4. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
5. Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet.
Yang H; Fang J; Jia X; Han C; Chen X; Yang CS; Li N
Carcinogenesis; 2011 Mar; 32(3):381-8. PubMed ID: 21186300
[TBL] [Abstract][Full Text] [Related]
6. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice.
Li W; Hua B; Saud SM; Lin H; Hou W; Matter MS; Jia L; Colburn NH; Young MR
Mol Carcinog; 2015 Oct; 54(10):1096-109. PubMed ID: 24838344
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
8. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
[TBL] [Abstract][Full Text] [Related]
9. miR-199a-3p suppresses progression of esophageal squamous cell carcinoma through inhibiting mTOR/p70S6K pathway.
Hou G; Wang Y; Zhang M; Hu Y; Zhao Y; Jia A; Wang P; Zhao W; Zhao W; Lu Z
Anticancer Drugs; 2021 Feb; 32(2):157-167. PubMed ID: 32826415
[TBL] [Abstract][Full Text] [Related]
10. Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: the possible role of nuclear factor kappaB signaling pathway.
Yang H; Jia X; Chen X; Yang CS; Li N
Int J Cancer; 2012 Oct; 131(7):1517-27. PubMed ID: 22223226
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.
Wang S; Lin Y; Xiong X; Wang L; Guo Y; Chen Y; Chen S; Wang G; Lin P; Chen H; Yeung SJ; Bremer E; Zhang H
Clin Cancer Res; 2020 Sep; 26(18):4921-4932. PubMed ID: 32646922
[TBL] [Abstract][Full Text] [Related]
12. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
13. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
14. Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Cheng K; Hao M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916907
[TBL] [Abstract][Full Text] [Related]
15. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
16. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.
Vitale-Cross L; Molinolo AA; Martin D; Younis RH; Maruyama T; Patel V; Chen W; Schneider A; Gutkind JS
Cancer Prev Res (Phila); 2012 Apr; 5(4):562-73. PubMed ID: 22467081
[TBL] [Abstract][Full Text] [Related]
17. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo.
Zhang T; Guo P; Zhang Y; Xiong H; Yu X; Xu S; Wang X; He D; Jin X
Int J Mol Sci; 2013 Dec; 14(12):24603-18. PubMed ID: 24351837
[TBL] [Abstract][Full Text] [Related]
18. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.
Feng Y; Ke C; Tang Q; Dong H; Zheng X; Lin W; Ke J; Huang J; Yeung SC; Zhang H
Cell Death Dis; 2014 Feb; 5(2):e1088. PubMed ID: 24577086
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation.
Li SH; Lu HI; Chang AY; Huang WT; Lin WC; Lee CC; Tien WY; Lan YC; Tsai HT; Chen CH
Oncotarget; 2016 Oct; 7(41):67150-67165. PubMed ID: 27564102
[TBL] [Abstract][Full Text] [Related]
20. Ets2 knockdown inhibits tumorigenesis in esophageal squamous cell carcinoma in vivo and in vitro.
Li Q; Yang L; Han K; Zhu L; Zhang Y; Ma S; Zhang K; Yang B; Guan F
Oncotarget; 2016 Sep; 7(38):61458-61468. PubMed ID: 27556183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
